RecruitingNCT06202131
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
Prospective Single-center Study About the Use of Ctdna in the Management of Patients With Tumors of the Gastrointestinal Tract
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
100 participants
Start Date
Nov 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study will evaluate the use of ctDNA in the clinical management of patients with tumors of the gastrointestinal tract.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria6
- Age \>18 years
- PS ECOG \<2;
- Histological diagnosis of gastrointestinal cancer: esophageal, gastric, intestinal, pancreatic, biliary tract neoplasms;
- Radiological evidence of resectable/locally advanced/metastatic disease on the date of signing the written informed consent;
- Adequate organ and function;
- Availability of tumor histological material.
Exclusion Criteria2
- No histological diagnosis of neoplasia of the gastrointestinal tract.
- No written informed consent.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06202131
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT058069319 locations
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
NCT068029912 locations